Thor Medical ASA (TRMED.OL) Stock Analysis & Winston Score

Thor Medical ASA is a Norwegian biotechnology company focused on producing a radioactive substance called Thorium-227, which is used to treat cancer. The company supplies this material to pharmaceutical partners who use it to build targeted cancer therapies, a treatment approach called targeted alpha therapy (TAT). Thor Medical does not make finished drugs itself — it sits earlier in the supply chain, providing a critical raw ingredient. The company earns revenue through supply agreements and partnerships with larger drug developers, rather than selling medicines directly to patients. It operates primarily out of Norway and is considered a small, early-stage company with no meaningful revenue yet, which explains its zero gross margin. Thor Medical's main competitive advantage is its control over Thorium-227 production and supply, which is a rare and difficult material to produce at scale. The key risk is that the company depends entirely on its partners successfully developing approved drugs — if those programs fail in clinical trials, Thor Medical loses its path to revenue.